Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hyperfine Says Question Is When, Not If, Portable MRI Will Impact The World; CEO Dave Scott Discusses

Executive Summary

Hyperfine, which markets the first US FDA-cleared portable MRI system, is facing COVID-related headwinds in bringing its system to hospitals, but CEO Dave Scott says wider adoption of the disruptive solution is inevitable. The company is going public today after combining with the HealthCor Catalio Acquisition Corp.

You may also be interested in...



‘The Story That No One Likes To Hear’: Investors Looking For Surer Bets In Health Tech After Record 2021

A panel of investors and leaders in healtech expects investment in health tech to decline, but still foresees opportunities for companies working on solutions that will transform overall health care such as AI, ML, mental health and health equity.

Philips Announces CEO Succession In Midst Of Massive Recall

Philips CEO Frans van Houten will leave the company in October amid a massive recall of ventilators and related products. Roy Jakobs will succeed van Houten as CEO and president effective 15 October, Philips said.

De Oro Devices’ Nex(t)Stride To Help Freezing Gait Is Expand Into Other Diseases, Add Software

De Oro Devices’ plans to add more indications for its portable device for freezing gait associated with Parkinson’s disease. In 2023, the company hopes to address , multiple sclerosis, stroke and cerebral palsy, and add mobility-gait software.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT144882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel